Loading...
Loading...
GE Healthcare today announced that regulatory bodies in the United
States and Europe have accepted its applications for review of the
investigational PET amyloid imaging agent [18F]flutemetamol,
a positron emission tomography (PET) imaging agent. A New Drug
Application (NDA) was submitted to the U.S. Food and Drug Administration
(FDA) for [18F]flutemetamol use in the visual detection of
beta amyloid in the brains of adult patients with cognitive impairment
who are being evaluated for Alzheimer's disease (AD) or other cognitive
disorders. Additionally, a Marketing Authorisation Application (MAA) was
submitted to the European Medicines Agency for [18F]flutemetamol
use in the visual detection of beta amyloid in the brains of adult
patients who are being evaluated for AD.
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in